ANIP: ANI Pharmaceuticals, Inc. Stock

by  •  • Comments Off on ANIP: ANI Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,239.78
Enterprise Value ($M) 1,743.86
Book Value ($M) 428.53
Book Value / Share 21.10
Price / Book 2.89
NCAV ($M) -327.48
NCAV / Share -16.13
Price / NCAV -3.79

Profitability (mra)
Return on Invested Capital (ROIC) -0.02
Return on Assets (ROA) -0.02
Return on Equity (ROE) -0.04

Liquidity (mrq)
Quick Ratio 2.02
Current Ratio 2.72

Balance Sheet (mrq) ($M)
Current Assets 527.68
Assets 1,283.70
Liabilities 855.17
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 614.38
Operating Income 14.62
Net Income -18.52
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 64.02
Cash from Investing -404.72
Cash from Financing 264.94

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-21 13G Millennium Management Llc 5.20
11-13 13G/A Rubric Capital Management LP 0.27 -94.96
03-14 13D/A Meridian Venture Partners II GP, L.P. 6.90 -13.88
2024-02-13 13G Vanguard Group Inc 6.31

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT UNDER SECTION
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT UNDER SECTION 13 OR
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT UNDER SECTION 13 O

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 97,557 343,234 28.42
2025-03-06 53,199 255,883 20.79
2025-03-05 58,578 209,581 27.95
2025-03-04 41,213 172,546 23.89

(click for more detail)

Similar Companies
ADMA – ADMA Biologics, Inc. AFMD – Affimed N.V.
ALT – Altimmune, Inc. APGE – Apogee Therapeutics, Inc.
APLT – Applied Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io